Tea infusions of wormwood plant cured schistosomiasis faster than commonly used drug in clinical trial

December 7, 2018 by Michael W. Dorsey, Worcester Polytechnic Institute
WPI biologist Pamela Weathers with the plant Artemisia annua, or sweet wormwood, which performed better that the frontline drug against the tropical disease schistosomiases in a clinical trial she helped run in Africa. Credit: Worcester Polytechnic Institute

Tea infusions made from two species of the wormwood plant cured the tropical disease schistosomiasis significantly faster than the drug most commonly used against the ailment—and with no adverse side effects—in a large clinical trial conducted in the Democratic Republic of Congo. The study's authors, including a professor and two research associates at Worcester Polytechnic Institute (WPI), say the treatment should be considered for implementation on a global scale.

Schistosomiasis, which is caused by parasitic flatworms, affects nearly 210 million people worldwide, primarily in Africa, Asia, and South America, and is responsible for about 200,000 deaths each year, according to the World Health Organization. Infecting the intestines and urinary tract, it causes a range of symptoms, including abdominal pain and diarrhea, and in more severe case can lead to liver damage, kidney failure, and even bladder cancer. The only cost-effective treatment is praziquantel, or PZQ, a drug used to treat a number of parasitic worm infections.

Previous clinical trials have shown that the effectiveness of PZQ is enhanced when it is administered along with one of three anti-malarial drugs: artemisinin, artesunate, or artemether. Artemisinin is a chemical derived from the sweet wormwood plant, Artemisia annua, while the other two are chemically synthesized from artemisinin. While artesunate alone was found to be less effective than PZQ at eliminating the disease in the same trial, anecdotal reports suggest that a tea made from the Artemisia annua plant has been used successfully as a treatment for .

"In , we showed that ingesting the dried leaves of Artemisia annua effectively eliminates the parasite that causes malaria," said Pamela Weathers, professor of biology and biotechnology at WPI, a co-author of the new study who is also currently overseeing the first clinical trial involving the use of dried leaf Artemisia (DLA) against malaria. "Some of the plant's antimalarial properties would be expected to have a similar effect on the schistosomiasis parasite, so it made sense to explore the effects of orally ingested leaves of the plant on that disease, as well."

In the study conducted by researchers in Africa, Europe, and the United States and published in the journal Phytomedicine ("Effect of Artemisia annua and Artemisia afra tea infusions on schistosomiasis in a large clinical trial," December 2018), 800 patients from Maniema Province in the Democratic Republic of Congo (DRC) who exhibited signs of schistosomiasis infection were assigned to one of three groups. One group was treated with PZQ, while patients in the other two drank about a third of a liter of a tea infusion made from the dried leaves and twigs of either Artemisia annua or Artemisia afra (another member of the wormwood genus) three times daily. Patients were considered cured when no more parasite eggs were found in their stool samples.

The results showed that both of the Artemisia tea infusions were just as effective in eliminating the parasite as PZQ, but that they achieved that result in two-thirds of the time—14 days, vs. 21 days for PZQ. And while many of the patients receiving PZQ suffered (more than 18 percent experienced abdominal pain, for example, and more than 26 percent had headaches), no side effects were reported among those who consumed the teas.

"This is an important study with promising results" said Lucile Cornet-Vernet, vice president of La Maison de l'Artemisia, a non-governmental organization in Paris, the corresponding author of the Phytomedicine paper. "It points to the need for more studies like this to better understand the medicinal value of Artemisia. Finding support for such studies has proven challenging, but it is important that we try, since this work benefits humanity."

Artemisia annua is categorized as a "generally recognized as safe" (GRAS) medicinal herb by the U.S. Food and Drug Administration, which means it is safe to add to foods and can be consumed without adverse effects. Made into a tea, the plant has been consumed as a remedy for malaria for hundreds of years in Asia, though it was not until 1972 that Chinese scientist Tu Youyou isolated artemisinin from the plant and demonstrated its effectiveness against malaria, a discovery that won her the 2015 Nobel Prize in Medicine.

Weathers said one of the most intriguing aspects of the results of the clinical trial in the DRC is that extracts of both species of wormwood were effective against schistosomiasis, even though only one, Artemisia annua, contains artemisinin (Artemisia afra has been found to contain, at most, trace amounts). "Each species of Artemisia contains a unique, complex mixture of phytochemicals, a number of which have been shown to have antimalarial properties," Weathers said. "The results of this study make it clear that the effectiveness of Artemisia against schistosomiasis and malaria is not due to artemisinin, alone. The plants should really be considered rich combination therapies."

In her research, Weathers has compared the effectiveness of administering the dried leaves of Artemisia annua, ground up and made into tablets or capsules, to that of the standard malarial treatment, artemisinin combination therapy, or ACT, in which artemisinin is combined with one or more other anti-malarial drugs. In animal trials, her team has shown that the body more readily absorbs artemisinin from the plant than from the drug, that the plant-based therapy is more effective in eliminating the malaria parasite, and that the plant-based therapy may avoid the problem of drug resistance.Weathers believes that these differences between ACT and DLA are due to the presence of the other phytochemicals with medicinal properties in DLA.

Weathers noted that Artemisia's utility as a medicine goes beyond its demonstrated effectiveness as a treatment for schistosomiases and malaria. She said many species of wormwood, including Artemisia annua and Artemisia afra, grow naturally in areas of the world where tropical diseases are rampant and that the processes of growing, harvesting, and processing the plant and producing the DLA capsules or tablets can be done locally and even become the basis for local businesses, which could significantly lower the cost of treating these diseases and increase the availability of effective treatments.

Also, Weathers noted that while the schistosomiasis trial tested the effectiveness of tea infusions, she has chosen to focus her own studies on the efficacy of ingesting the plant, itself. "Tea infusions are the traditional way to get the benefits of Artemisia, but they have some disadvantages," she said. "First, the tea must be prepared carefully to ensure that the beneficial compounds from the plant end up in the tea, and this may not be easy for everyone to do. Second, for many people, the tea will taste very bitter, and may simply not be palatable to some patients, especially children. With the tablets and capsules containing the dried plant, the dosage can be carefully controlled, storage is possible, and most people have no problem consuming them."

Cornet-Vernet said that her organization will continue to focus on tea infusions since she believes that they offer a more affordable option for the poorest residents of Africa and other areas impacted by tropical diseases. In addition, she said the widespread problem of fraudulent medications in Africa has led her non-governmental organization to favor a treatment that people can create themselves, from they grow on their own property. "People in Africa are used to making tea infusions," she said. "This is something that is very familiar to them, and it can save lives."

Explore further: New whole plant therapy shows promise as an effective and economical treatment for malaria

More information: Jérôme Munyangi et al. Effect of Artemisia annua and Artemisia afra tea infusions on schistosomiasis in a large clinical trial, Phytomedicine (2018). DOI: 10.1016/j.phymed.2018.10.014

Related Stories

New whole plant therapy shows promise as an effective and economical treatment for malaria

December 20, 2012
In the worldwide battle to curtail malaria, one of the most prevalent and deadly infectious diseases of the developing world, drug after drug has fallen by the wayside as the malaria parasite has become resistant to it. Only ...

Patients with drug-resistant malaria cured by plant therapy

April 24, 2017
When the standard malaria medications failed to help 18 critically ill patients, the attending physician in a Congo clinic acted under the "compassionate use" doctrine and prescribed a not-yet-approved malaria therapy made ...

Transgenic plants against malaria

March 27, 2017
Scientists have discovered a gene that allows to double the production of artemisinin in the Artemisia annua plant.The artemisinin-based combination therapy (ACT) is the standard treatment for malaria worldwide, endorsed ...

York's anti-malarial plant given Chinese approval

April 24, 2015
A new hybrid plant used in anti-malarial drug production, developed by scientists at the University of York's Centre for Novel Agricultural Products (CNAP), is now registered as a new variety in China.

Engineered Chinese shrub produces high levels of antimalarial compound

April 24, 2018
Artemisinin is a potent antimalarial compound produced naturally by the Chinese shrub Artemisia annua, commonly known as sweet wormwood. Currently,however, the low amount of artemisinin produced in the leaves of this plant ...

New process would make anti-malarial drug less costly

May 23, 2012
Scientists are reporting development of a new, higher-yield, two-step, less costly process that may ease supply problems and zigzagging prices for the raw material essential for making the mainstay drug for malaria. That ...

Recommended for you

Study identifies a key cellular mechanism that triggers pneumonia in humans

December 11, 2018
The relationship between influenza and pneumonia has long been observed by health workers. Its genetic and cellular mechanisms have now been investigated in depth by scientists in a study involving volunteers and conducted ...

Effect of oral alfacalcidol on clinical outcomes in patients without secondary hyperparathyroidism

December 11, 2018
Treatment with active vitamin D did not decrease cardiovascular events in kidney patients undergoing hemodialysis, according to a research group in Japan. They have reported their research results in the December 11 issue ...

Human antibody discovery could save lives from fungal killer

December 11, 2018
A new way to diagnose, treat and protect against stealth fungal infections that claim more than 1.5 million lives per year worldwide has been moved a step closer, according to research published in Nature Communications.

Dialysis patients at risk of progressive brain injury

December 10, 2018
Kidney dialysis can cause short-term 'cerebral stunning' and may be associated with progressive brain injury in those who receive the treatment for many years. For many patients with kidney failure awaiting a kidney transplant ...

Silicosis is on the rise, but is there a therapeutic target?

December 6, 2018
Researchers from the CNRS, the University of Orléans, and the company Artimmune, in collaboration with Turkish clinicians from Atatürk University, have identified a key mechanism of lung inflammation induced by silica exposure, ...

PET scans to optimize tuberculosis meningitis treatments and personalize care, study finds

December 6, 2018
Although relatively rare in the United States, and accounting for fewer than 5 percent of tuberculosis cases worldwide, TB of the brain—or tuberculosis meningitis (TBM)—is often deadly, always hard to treat, and a particular ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.